Relapses in patients with antineutrophil cytoplasmic autoantibody- associated vasculitis: Likely to begin with the same organ as initial onset

Journal of Rheumatology

Volumn 35, Issue 3, 2008, Pages 448-450

  Chen, Min ^b   Yu, Feng ^b   Zhao, Ming Hui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NONE

Author keywords

Antineutrophil cytoplasmic antibodies; Relapse; Vasculitis

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; RECURRENT DISEASE;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; WEGENER GRANULOMATOSIS;

EID: 40649089193     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76-85.
2. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
3. Chen M, Yu F, Zhang Y, Zhao MH. Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single center. Postgrad Med J 2005;81:723-7.
4. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on ANCA-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
5. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
6. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005;143:621-31.
7. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
8. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
9. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003,349:36-44.
10. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
11. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776-84.
12. Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. Q J Med 1993;86:779-89.
13. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004;51:269-73.
14. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005;352:330-2.